Verrica Pharmaceuticals Inc (VRCA) Institutional Ownership Tracker (Q2 2026)

VRCA ranks #6507 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

44 institutions disclose a position in VRCA, but none treat it as a major bet — even Cannell Capital LLC, its most concentrated holder, allocates just 3.2% of its own portfolio to it.

BlackRock has added to its VRCA position for two straight quarters, increasing it by $407.7K to reach $455.0K today.

Armistice Capital, LLC has trimmed its VRCA position for two straight quarters, cutting it by $6.7M while still holding $2.6M.

VRCA is up 1.4% today, and institutions have been net buyers of $1.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

VRCA reported a net loss of $31.2M over the trailing twelve months.

• Not yet profitable — net loss of $31.2M over the trailing twelve months
• Revenue grew 106.2% year over year
• Net income improved year over year, from -$48.6M to -$31.2M
• Operating cash flow was negative, using $17.6M in cash
• Current ratio of 2.59x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.90x equity — within a conventional range